Janssen Pharmaceuticals, Inc., a Johnson & Johnson company, has acquired XO1 Ltd., a privately held virtual biopharma company founded to develop the anti-thrombin antibody ichorcumab. Financial terms were not disclosed.   Ichorcumab is a recombinant human antibody developed to mimic the activity of a human antibody designed to produce an anticoagulated state without predisposition to bleeding.   XO1 licensed the technology for Ichorcumab from Cambridge Enterprise to take its development towa...